YSB Inc. posts strong 2025 earnings as digital pharma platform strategy pays off

YSB Inc. ( (HK:9885) ) has issued an update.

YSB Inc. reported robust results for 2025, with revenue rising 17.1% year on year to RMB20.97 billion, driven mainly by an 18.2% increase in its self-operation business while online marketplace revenue dipped slightly. Gross profit climbed 27.2% to RMB2.31 billion and profit attributable to owners surged more than fourfold to RMB152.97 million, lifting adjusted net profit by 51.2% and allowing a higher dividend per share.

Management said the group is capitalising on China’s policy-backed “Healthy China” agenda, demographic ageing and rising health consumption to strengthen its position in the outside-of-hospital pharmaceutical market. By deepening digitalisation, refining operations and co-developing service models with upstream and downstream partners, YSB is turning its platform from a transaction facilitator into an industry collaboration network, enhancing competitiveness through supply-chain efficiency, data-driven matching and professional services.

More about YSB Inc.

YSB Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in China’s pharmaceutical and healthcare distribution sector with a focus on the outside-of-hospital market. The Group runs a dual-engine model combining a self-operation business with an online marketplace, serving hundreds of thousands of downstream terminals and collaborating with over 11,000 upstream sellers to provide digital, data-driven supply-chain and procurement services.

Average Trading Volume: 8,303,597

Technical Sentiment Signal: Hold

Current Market Cap: HK$3.05B

For detailed information about 9885 stock, go to TipRanks’ Stock Analysis page.